Literature DB >> 23807378

Novel therapies for hepatitis C - one pill fits all?

Michael P Manns1, Thomas von Hahn.   

Abstract

Almost 25 years after the hepatitis C virus (HCV) was identified, and following intense research and development efforts, a large number of direct-acting antiviral drugs are now beginning to reach patient care. Accordingly, the way in which care is delivered is evolving at a breath-taking pace. Here, we review the current and upcoming treatment options for HCV, describe the key challenges facing clinicians and drug developers and discuss how the landscape in the HCV arena will change over the coming years.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23807378     DOI： 10.1038/nrd4050

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  100 in total

Review 1.  Treatment of patients with genotype 3 chronic hepatitis C--current and future therapies.

Authors:  Shiv K Sarin; Chandan K N Kumar
Journal:  Liver Int       Date:  2012-02       Impact factor: 5.828

2.  Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C.

Authors:  Edmondo Falleti; Davide Bitetto; Carlo Fabris; Giovanna Fattovich; Annarosa Cussigh; Sara Cmet; Elisa Ceriani; Ezio Fornasiere; Michela Pasino; Donatella Ieluzzi; Mario Pirisi; Pierluigi Toniutto
Journal:  Hepatology       Date:  2012-10-14       Impact factor: 17.425

3.  Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

Authors:  Holger Hinrichsen; Yves Benhamou; Heiner Wedemeyer; Markus Reiser; Roel E Sentjens; José L Calleja; Xavier Forns; Andreas Erhardt; Jens Crönlein; Ricardo L Chaves; Chan-Loi Yong; Gerhard Nehmiz; Gerhard G Steinmann
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

4.  The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.

Authors:  Robert Flisiak; Saya V Feinman; Maciej Jablkowski; Andrzej Horban; Wieslaw Kryczka; Małgorzata Pawlowska; Jenny E Heathcote; Giuseppe Mazzella; Carmen Vandelli; Valérie Nicolas-Métral; Pierre Grosgurin; Jorge S Liz; Pietro Scalfaro; Hervé Porchet; Raf Crabbé
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

5.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

6.  Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.

Authors:  Sarah Maylin; Michelle Martinot-Peignoux; Rami Moucari; Nathalie Boyer; Marie-Pierre Ripault; Dominique Cazals-Hatem; Nathalie Giuily; Corinne Castelnau; Ana Carolina Cardoso; Tarik Asselah; Cyrille Féray; Marie Hélène Nicolas-Chanoine; Pierre Bedossa; Patrick Marcellin
Journal:  Gastroenterology       Date:  2008-05-21       Impact factor: 22.682

7.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

8.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

9.  Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase.

Authors:  Timothy L Tellinghuisen; Joseph Marcotrigiano; Charles M Rice
Journal:  Nature       Date:  2005-05-19       Impact factor: 49.962

Review 10.  Genetic diversity and evolution of hepatitis C virus--15 years on.

Authors:  Peter Simmonds
Journal:  J Gen Virol       Date:  2004-11       Impact factor: 3.891
View more
  73 in total

1.  Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C.

Authors:  Juan Pablo Trivella; Julio Gutierrez; Paul Martin
Journal:  Expert Opin Pharmacother       Date:  2015-02-09       Impact factor: 3.889

2.  Aryl-substituted aminobenzimidazoles targeting the hepatitis C virus internal ribosome entry site.

Authors:  Kejia Ding; Annie Wang; Mark A Boerneke; Sergey M Dibrov; Thomas Hermann
Journal:  Bioorg Med Chem Lett       Date:  2014-05-14       Impact factor: 2.823

Review 3.  Therapeutic Approaches for Zika Virus Infection of the Nervous System.

Authors:  Rachel P M Abrams; Jamie Solis; Avindra Nath
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 4.  Hepatitis C virus reinfection after liver transplant: New chances and new challenges in the era of direct-acting antiviral agents.

Authors:  Kerstin Herzer; Guido Gerken
Journal:  World J Hepatol       Date:  2015-03-27

5.  Mechanisms of activation and inhibition of Zika virus NS2B-NS3 protease.

Authors:  Xia Chen; Kailin Yang; Chen Wu; Cheng Chen; Can Hu; Olga Buzovetsky; Zefang Wang; Xiaoyun Ji; Yong Xiong; Haitao Yang
Journal:  Cell Res       Date:  2016-10-18       Impact factor: 25.617

6.  Rapamycin modulation of p70 S6 kinase signaling inhibits Rift Valley fever virus pathogenesis.

Authors:  Todd M Bell; Virginia Espina; Svetlana Senina; Caitlin Woodson; Ashwini Brahms; Brian Carey; Shih-Chao Lin; Lindsay Lundberg; Chelsea Pinkham; Alan Baer; Claudius Mueller; Elizabeth A Chlipala; Faye Sharman; Cynthia de la Fuente; Lance Liotta; Kylene Kehn-Hall
Journal:  Antiviral Res       Date:  2017-04-23       Impact factor: 5.970

7.  Hepatitis C virus replication compartment formation: mechanism and drug target.

Authors:  Vineela Chukkapalli; Glenn Randall
Journal:  Gastroenterology       Date:  2014-03-25       Impact factor: 22.682

Review 8.  Current and potential treatments for ubiquitous but neglected herpesvirus infections.

Authors:  Jonathan E Gable; Timothy M Acker; Charles S Craik
Journal:  Chem Rev       Date:  2014-10-02       Impact factor: 60.622

9.  Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.

Authors:  Muriel Lavie; Stéphane Sarrazin; Roland Montserret; Véronique Descamps; Thomas F Baumert; Gilles Duverlie; Karin Séron; François Penin; Jean Dubuisson
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

10.  Expression profile and kinetics of cytokines and chemokines in patients with chronic hepatitis C.

Authors:  Zhen-Qi Han; Tao Huang; Yong-Zhi Deng; Guang-Ze Zhu
Journal:  Int J Clin Exp Med       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.